What is Metsera?
Metsera operates at the intersection of advanced pharmacology and metabolic health, positioning itself as a leader in the next generation of weight loss treatments. By advancing both oral and injectable incretin and non-incretin therapies, the firm is targeting multiple biological pathways to deliver best-in-class clinical outcomes. Its strategic focus on a broad, multi-target portfolio allows the company to navigate the rapidly evolving landscape of metabolic medicine with agility and scientific rigor, effectively bridging the gap between laboratory innovation and patient-centric clinical application.
How much funding has Metsera raised?
Metsera has raised a total of $505M across 2 funding rounds:
Other Financing Round
$290M
Series B
$215M
Other Financing Round (2024): $290M with participation from GV, F-Prime Capital Partners, and ARCH Venture Partners
Series B (2024): $215M led by Fidelity Management Services, Softbank Vision Fund, ARCH Venture Partners, Venrock, Alpha Wave Ventures, RA Capital Management, Deep Track Capital, Viking Global Investors, Janus Henderson Investors, and Wellington Management
Key Investors in Metsera
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, supported by their internal scientific think tank, TechAtlas.
GV
A global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
What's next for Metsera?
With the recent capital injection, Metsera is well-positioned to scale its clinical development programs and expand its research infrastructure. The company's roadmap involves transitioning its lead candidates through critical trial phases while refining its proprietary delivery platforms. As the demand for effective metabolic interventions continues to surge, Metsera's ability to leverage its robust financial backing will be instrumental in maintaining its competitive edge and accelerating the path to commercialization for its pipeline of transformative medicines.
See full Metsera company page
